EXOZ

8-K - EXOZYMES INC. (0002010788) (Filer)

LOS ANGELES, CA / ACCESS Newswire / June 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the pricing of its public offering of units, each consisting of two shares of common stock and one common stock purchase warrant.The Company has sold 592,270 shares of common stock together with 296,135 warrants as units, each unit consisting of two shares of common stock and one warrant to purchase one share of common stock. The units will separate immediately upon issuance and all shares of common stock and warrants that comprise the units are being is

424B5 - EXOZYMES INC. (0002010788) (Filer)

424B5 - EXOZYMES INC. (0002010788) (Filer)

424B5 - EXOZYMES INC. (0002010788) (Filer)

10-Q - EXOZYMES INC. (0002010788) (Filer)

LOS ANGELES, CA / ACCESS Newswire / May 7, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into nutraceuticals, novel medicines, and valuable chemicals - announced its graduation from the Shell GameChanger™ Accelerator, a multimillion-dollar, multiyear program developed in collaboration between Shell and the U.S. Department of Energy's National Laboratory of the Rockies (NLR).From 2023 to 2026, eXoZymes partnered with GCxN to advance the next generation of transformative technologies with the potential to dramatically alter the future global energy landscape. The collaboration helped advance eXoZymes' cell-free bioma

8-K - EXOZYMES INC. (0002010788) (Filer)

8-K - EXOZYMES INC. (0002010788) (Filer)

4 - EXOZYMES INC. (0002010788) (Issuer)

LOS ANGELES, CA / ACCESS Newswire / April 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced that Chief Commercial Officer, Damien Perriman was featured on the latest episode of the industry leading Grow Everything podcast to discuss the company's first spinout, NCTx, and how eXoZymes is building a repeatable commercialization model for high-value natural products.The Grow Everything podcast is co-hosted by biotech experts, Erum Azeez Khan and Karl Schmieder. Previous episodes have featured guests - including key individuals from companies like NVIDIA, P&

424B5 - EXOZYMES INC. (0002010788) (Filer)

4 - EXOZYMES INC. (0002010788) (Issuer)

3 - EXOZYMES INC. (0002010788) (Issuer)

4 - EXOZYMES INC. (0002010788) (Issuer)

4 - EXOZYMES INC. (0002010788) (Issuer)

4 - EXOZYMES INC. (0002010788) (Issuer)

4 - EXOZYMES INC. (0002010788) (Issuer)

Management to Host Conference Call Today at 5:30 PM EasternLOS ANGELES, CA / ACCESS Newswire / March 31, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - provides an update on operations through the fiscal year ended December 31, 2025.Michael Heltzen, CEO of eXoZymes, states, "We've moved beyond our 'big idea' potential and into execution - building differentiated assets and capabilities in a capital-efficient way that we believe sets us apart. We expect to see further value generating inflection points as programs like NCT and our cannabinoid initiatives continue to

Addison, TX, March 31, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-defining disruptive technology companies, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025. More Detailed Information 2025 Annual Shareholder Letter HERE. Form 10-K HERE. Key Assets and Strategic Developments eXoZymes (NASDAQ:EXOZ): MDB holds approximately 4.1 million shares and warrants, valued at approximately $30 million based on March 30, 2026 market prices. The company is advancing cell-free biomanufacturing with large, ownable opportunities and clear commercialization

8-K - EXOZYMES INC. (0002010788) (Filer)

10-K - EXOZYMES INC. (0002010788) (Filer)

LOS ANGELES, CA / ACCESS Newswire / March 25, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Tuesday, March 31, 2026 at 5:30 PM Eastern Time to discuss its results for the fourth quarter and full year 2025. A press release detailing these results will be issued prior to the call.CEO of eXoZymes, Michael Heltzen, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period.Investors can pre

LOS ANGELES, CA / ACCESS Newswire / March 18, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced an important validation and de-risking milestone for its cell-free biomanufacturing platform: An independent partner, Cayman Chemical, successfully ran eXoZymes' technology at pilot scale and achieved results consistent with - and in some cases exceeding - earlier internal runs.Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing, and analysis ind

LOS ANGELES, CA / ACCESS Newswire / March 12, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced that Perriman will present a solution for scaling production of NCT, a naturally occurring small molecule currently being developed by eXoZymes for both nutraceutical and pharmaceutical applications.The presentation will focus on NCT's potential role in metabolic health and its emerging relevance in the rapidly evolving landscape of food, supplements, and longevity-focused wellness solutions.The March 18, 2026, MISTA Symposium Healthspan event in San Francisco bri